Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: The Best Of Earnings And The Worse Of Earnings

This article was originally published in Scrip

Executive Summary

Last week, approaching the end of this third-quarter earnings season, it seemed that all the good and all the bad events that investors could expect happened in the same week. On the positive side, the acquisitions of the biotechnology companies Dyax Corp. and ZS Pharma, Inc. were announced, Lexicon Pharmaceuticals, Inc. licensed its Phase III-ready product to Sanofi, and the NASDAQ Biotchnology Index (NBI) finished the week just into positive territory after a gut-wrenching down-day on Thursday.



Related Companies